Argenx reports $398M Q1 2024 net product sales driven by severe autoimmune disease focus and VYVGART approval in 30+ countries.
Argenx, a global immunology company, reported $398M in Q1 2024 net product sales, driven by its severe autoimmune disease focus and VYVGART, approved in 30+ countries for generalized myasthenia gravis and Japan for ITP. VYVGART is available as IV and SC injections, and the company is advancing its pipeline, with efgartigimod under evaluation in 15 indications by 2025. Other pipeline programs include empasiprubart and ARGX-119.
May 09, 2024
3 Articles